Ameliorative Effect of Cannabidiol on Topiramate-Induced Memory Loss: The Role of Hippocampal and Prefrontal Cortical NMDA Receptors and CREB/BDNF Signaling Pathways in Rats
Neurochemical Research · 2024
DOI: 10.1007/s11064-023-04041-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemical Research, 2024. Verfasst von Helia Aghamiri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Cannabidiol. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Iran University of Medical Sciences.
Abstract (Originalsprache)
Cannabidiol (CBD) is a promising neurological agent with potential beneficial effects on memory and cognitive function. The combination of CBD and topiramate in the treatment of some neurological diseases has been of great interest. Since Topiramate-induced memory loss is a major drawback of its clinical application and the overall effect of the combination of CBD and topiramate on memory is still unclear, here we investigated the effect of CBD on topiramate-induced memory loss and the underlying molecular mechanisms. A one trial step-through inhibitory test was used to evaluate memory consolidation in rats. Moreover, the role of N-methyl-D-aspartate receptors (NMDARs) in the combination of CBD and topiramate in memory consolidation was evaluated through the intra-CA1 administration of MK-801 and NMDA. Western blot analysis was used to evaluate variations in brain-derived neurotrophic factor (BDNF) and phosphorylated cyclic AMP response element-binding protein (pCREB)/CREB ratio in the prefrontal cortex (PFC) and hippocampus (HPC). While the intraperitoneal (i.p.) administration of topiramate (50, 75, and 100 mg/kg) significantly reduced inhibitory time latency, the i.p. administration of CBD (20 and 40 mg/kg) could effectively reverse these effects. Similarly, the sub-effective doses of NMDA plus CBD (10 mg/kg) could improve the topiramate-induced memory loss along with an enhancement in BDNF and pCREB expression in the PFC and HPC. Contrarily, the administration of sub-effective doses of the NMDAR antagonist (MK-801) diminished the protective effects of CBD (20 mg/kg) on topiramate-induced memory loss associated with decreased BDNF and pCREB levels in the PFC and HPC. These findings suggest that CBD can improve topiramate-induced memory impairment, partially by the NMDARs of the PFC and HPC, possibly regulated by the CREB/BDNF signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
- Department of Pharmacology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. jafarisabet.m@iums.ac.ir.
- Razi Drug Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. jafarisabet.m@iums.ac.ir.
- Razi Drug Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Förderung
- Iran University of Medical Sciences
Zitieren
APA
Aghamiri, H., Jafari-Sabet, M., & Hoormand, M. (2024). Ameliorative Effect of Cannabidiol on Topiramate-Induced Memory Loss: The Role of Hippocampal and Prefrontal Cortical NMDA Receptors and CREB/BDNF Signaling Pathways in Rats. Neurochemical Research. https://doi.org/10.1007/s11064-023-04041-4
Vancouver
Aghamiri H, Jafari-Sabet M, Hoormand M. Ameliorative Effect of Cannabidiol on Topiramate-Induced Memory Loss: The Role of Hippocampal and Prefrontal Cortical NMDA Receptors and CREB/BDNF Signaling Pathways in Rats. Neurochemical Research. 2024. doi:10.1007/s11064-023-04041-4
BibTeX
@article{Aghamiri2024,
author = {Aghamiri, Helia and Jafari-Sabet, Majid and Hoormand, Mahmood},
title = {Ameliorative Effect of Cannabidiol on Topiramate-Induced Memory Loss: The Role of Hippocampal and Prefrontal Cortical NMDA Receptors and CREB/BDNF Signaling Pathways in Rats},
journal = {Neurochemical Research},
year = {2024},
doi = {10.1007/s11064-023-04041-4}
}
EUVIMED